ERBB2 and metastatic neoplasm: Perhaps most importantly, certain biologic subtypes such as triple negative (TNBC) and Her2 positive (Her2+) patients with residual disease post chemotherapy, who are also the ones at highest risk of recurrence and metastatic disease, will now have the option to receive further effective adjuvant systemic therapies shown to improve disease-free survival [1,7,8,9].